Hepion pharmaceuticals urges shareholders to vote “for” all proposals ahead of its upcoming annual meeting

Edison, n.j., may 31, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and hepatocellular carcinoma (“hcc”), today urged its stockholders to vote “for” all proposals put forth in the definitive proxy statement prior to its june 24, 2022 annual meeting of stockholders.
HEPA Ratings Summary
HEPA Quant Ranking